Robert Baffi - BioMarin Pharmaceutical Insider

BioMarin Pharmaceutical Inc -- USA Stock  

USD 89.78  0.14  0.16%

Executive VP of Technical Operations

Dr. Robert A. Baffi, Ph.D., serves as an Executive Vice President Technical Operations of Biomarin Pharmaceutical Inc. From 2000 to December 2009, Dr. Baffi served as our Senior Vice President of Technical Operations. From 1986 to 2000, Dr. Baffi served in a number of increasingly responsible positions at Genentech, Inc., primarily in the functional area of quality control. Prior to Genentech, Dr. Baffi worked for Cooper BioMedical as a Research Scientist and at Becton Dickinson Research Center as a PostDoctoral Fellow. Dr. Baffi has contributed to more than 20 regulatory submissions for product approval in the United States and Europe and to more than 50 regulatory submissions for investigational new drug testing. He currently serves on the board for the National Institute for Bioprocessing Research Training
Age: 61  EVP Since 2009  MBA    
415-506-6700  www.biomarin.com
Baffi received a Ph.D., M. Phil and a B.S. in biochemistry from the City University of New York and an M.B.A. from Regis University.

Robert Baffi Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (2.29) % which means that it has lost $2.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (5.73) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 1.17 B in liabilities with Debt to Equity (D/E) ratio of 41.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioMarin Pharmaceutical Inc has Current Ratio of 4.81 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 8 records

EVP Since

Susan HallEndo International plc
2014
Brian BlaserAbbott Laboratories
2012
John CapekAbbott Laboratories
2015
Richard AshleyAbbott Laboratories
2004
Hubert AllenAbbott Laboratories
2013
Thomas FreymanAbbott Laboratories
2015
Giovanni MagniBio Rad Laboratories Inc
2014
Stuart ArbuckleVertex Pharmaceuticals Incorpor
2012

Entity Summary

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc (BMRN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 2,158 people. BioMarin Pharmaceutical is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add BioMarin Pharmaceutical Inc to your portfolio

Top Management

BioMarin Pharmaceutical Leadership Team
William Young, Director
Elaine Heron, Director, MBA
Dennis Slamon, Director, Ph.D
Henry Fuchs, President, Ph.D
Robert Hombach, Director, MBA
Brian Mueller, VP
G Davis, President
Bryan Lawlis, Director, Ph.D
JeanJacques Bienaime, Chairman, MBA
Kenneth Bate, Director, MBA
Jeff Ajer, President, MBA
Richard Meier, Director
Willard Dere, Director
Daniel Spiegelman, President, MBA
V Lawlis, Director, Ph.D
Kathryn Falberg, Director, MBA
Eric Davis, SVP
Pierre Lapalme, Chairman
Robert Baffi, EVP, MBA
Alan Lewis, Director, Ph.D
Richard Ranieri, President
David Pyott, Director, MBA
Michael Grey, Director

Stock Performance

BioMarin Pharmaceutical Performance Indicators